Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This review highlights MRD's role in treatment strategies for AML, suggesting implications for personalization and guidance in therapy decisions.

The study emphasizes the evolving role of measurable residual disease as a decision-making tool in acute myeloid leukaemia.
Evaluating the prognostic power of MRD in specific genetic subgroups significantly impacts treatment options.
Recent studies reveal gaps in evidence for MRD-guided treatment, indicating a need for further research.
MRD assessment influences decisions around allogeneic stem cell transplantation and maintenance therapy strategies.

Nachmias et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

This review highlights MRD's role in treatment strategies for AML, suggesting implications for personalization and guidance in therapy decisions.

The study emphasizes the evolving role of measurable residual disease as a decision-making tool in acute myeloid leukaemia.
Evaluating the prognostic power of MRD in specific genetic subgroups significantly impacts treatment options.
Recent studies reveal gaps in evidence for MRD-guided treatment, indicating a need for further research.
MRD assessment influences decisions around allogeneic stem cell transplantation and maintenance therapy strategies.

Nachmias et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark